NO20000990D0 - Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta> - Google Patents

Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta>

Info

Publication number
NO20000990D0
NO20000990D0 NO20000990A NO20000990A NO20000990D0 NO 20000990 D0 NO20000990 D0 NO 20000990D0 NO 20000990 A NO20000990 A NO 20000990A NO 20000990 A NO20000990 A NO 20000990A NO 20000990 D0 NO20000990 D0 NO 20000990D0
Authority
NO
Norway
Prior art keywords
methods
interferon
compositions
treatments
beta
Prior art date
Application number
NO20000990A
Other languages
English (en)
Other versions
NO20000990L (no
Inventor
James G Barsoum
Xiao-Qiang Qin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO20000990D0 publication Critical patent/NO20000990D0/no
Publication of NO20000990L publication Critical patent/NO20000990L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
NO20000990A 1997-08-29 2000-02-28 Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta> NO20000990L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
NO20000990D0 true NO20000990D0 (no) 2000-02-28
NO20000990L NO20000990L (no) 2000-05-02

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000990A NO20000990L (no) 1997-08-29 2000-02-28 Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta>

Country Status (25)

Country Link
EP (1) EP1007717B8 (no)
JP (3) JP4124565B2 (no)
KR (1) KR100699285B1 (no)
CN (1) CN100342019C (no)
AT (1) ATE316145T1 (no)
AU (1) AU740428B2 (no)
BR (1) BR9812138A (no)
CA (1) CA2300480C (no)
CY (1) CY1105029T1 (no)
CZ (2) CZ299095B6 (no)
DE (1) DE69833264T2 (no)
DK (1) DK1007717T3 (no)
EA (1) EA003256B1 (no)
EE (1) EE04873B1 (no)
ES (1) ES2257817T3 (no)
HK (1) HK1029599A1 (no)
HU (1) HU224422B1 (no)
IL (2) IL134593A0 (no)
IS (1) IS2318B (no)
NO (1) NO20000990L (no)
NZ (1) NZ503401A (no)
PT (1) PT1007717E (no)
SK (1) SK286821B6 (no)
TR (1) TR200000532T2 (no)
WO (1) WO1999010516A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1363676T3 (da) * 2001-01-22 2007-07-23 Biogen Idec Inc Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
KR20220025757A (ko) * 2019-06-01 2022-03-03 시벡 바이오테크놀로지스, 엘엘씨 진핵 세포에 유전자 편집 시스템을 전달하기 위한 박테리아 플랫폼

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
DK0707071T3 (da) * 1994-08-16 2003-11-17 Crucell Holland Bv Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
JP4124565B2 (ja) 2008-07-23
EA200000270A1 (ru) 2000-10-30
EA003256B1 (ru) 2003-02-27
IS5374A (is) 2000-02-11
CN1271391A (zh) 2000-10-25
HUP0002913A2 (hu) 2000-12-28
SK2482000A3 (en) 2000-08-14
KR20010023511A (ko) 2001-03-26
CN100342019C (zh) 2007-10-10
JP2005225888A (ja) 2005-08-25
IL134593A0 (en) 2001-04-30
WO1999010516A2 (en) 1999-03-04
NO20000990L (no) 2000-05-02
ATE316145T1 (de) 2006-02-15
IS2318B (is) 2007-11-15
ES2257817T3 (es) 2006-08-01
CZ297314B6 (cs) 2006-11-15
CY1105029T1 (el) 2010-03-03
EE200000102A (et) 2000-12-15
EE04873B1 (et) 2007-08-15
DE69833264D1 (de) 2006-04-06
BR9812138A (pt) 2000-07-18
DK1007717T3 (da) 2006-05-29
SK286821B6 (sk) 2009-06-05
EP1007717B8 (en) 2006-05-03
HUP0002913A3 (en) 2003-08-28
NZ503401A (en) 2003-01-31
JP4219335B2 (ja) 2009-02-04
CZ299095B6 (cs) 2008-04-23
AU9205198A (en) 1999-03-16
JP3953458B2 (ja) 2007-08-08
JP2001514010A (ja) 2001-09-11
HU224422B1 (hu) 2005-08-29
PT1007717E (pt) 2006-06-30
HK1029599A1 (en) 2001-04-06
CA2300480A1 (en) 1999-03-04
JP2004155786A (ja) 2004-06-03
IL134593A (en) 2007-06-17
CA2300480C (en) 2010-01-05
DE69833264T2 (de) 2006-09-28
AU740428B2 (en) 2001-11-01
CZ2000733A3 (cs) 2000-06-14
WO1999010516A3 (en) 1999-05-06
KR100699285B1 (ko) 2007-03-26
EP1007717B1 (en) 2006-01-18
EP1007717A2 (en) 2000-06-14
TR200000532T2 (tr) 2000-11-21

Similar Documents

Publication Publication Date Title
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
DE69426328T2 (de) Verwendung von mesothelialen zellen in der gentherapie
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
DE69213744D1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin-technologie
AR006188A1 (es) &#34;composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion&#34;.
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
NO991839L (no) FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-&lt;alfa&gt;-nukleinsyrer
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
DE69725754D1 (de) Eingekapselte Antikörper-produzierende Zellen
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
ATE355385T1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
PL351499A1 (en) Expression of heparin-binding protein in recombinant mammalian cells
HK1035206A1 (en) Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum.
BR9810046A (pt) Sequência de nucleotìdeos, vetor de expressão, célula hospedeira, proteìna de esperma de mamìfero, proteìna de esperma recombinante, proteìna 4, 1 e/ou 6,7 de esperma, composição farmacêutica, e, vacina contraceptiva
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application